At the 2018 American Society of Hematology meeting, Amir Fathi from Massachusetts General Hospital, Boston, US, discusses the results from a phase II study of alisertib, an aurora a kinase inhibitor, in combination with induction chemotherapy in high-risk, untreated patients with acute myeloid leukemia (AML). Alisertib combined with conventional induction, is efficacious and demonstrates a promising rate of remission and survival among patients with previously untreated high-risk AML.
Amir Fathi | ASH 2018 | Alisertib in combination with induction chemotherapy in high-risk patients with AML
Was this article informative? Thank you for your feedback!